A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Meng Wang Meng Wang
- Numéro de téléphone: 18622221623
- E-mail: 18622221623@pm.com
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Aged 18-75 years, male or female.
- Histologically or cytologically confirmed stage III unresectable NSCLC per AJCC 9th edition, judged unresectable by institutional MDT team.
- Confirmed HER2 alteration: HER2 mutation/amplification detected by tissue NGS, or HER2 protein overexpression (IHC 2+ or 3+).
- No prior systemic anti-tumor therapy for NSCLC; prior anti-tumor Chinese herbal medicine allowed if ≥2 weeks washout before first dose.
- At least 1 measurable target lesion per RECIST v1.1.
- ECOG performance status 0 or 1.
- Able to provide tumor tissue specimen (archival ≤6 months or newly biopsied non-irradiated lesion).
- FEV1 >1.0 L and FEV1% predicted >40% within past 3 months.
Adequate organ function within 7 days before first dose (no blood product/G-CSF support within 14 days):
- Hematology: WBC ≥3.0×10⁹/L, ANC ≥1.5×10⁹/L, PLT ≥100×10⁹/L, Hb ≥90g/L
- Liver: AST/ALT ≤2.5×ULN (≤5×ULN for liver metastasis), TBIL ≤1.5×ULN
- Renal: Serum Cr ≤1.5×ULN or CrCl ≥50 mL/min
- Cardiac: LVEF ≥50% by echocardiogram
- Fertile male/female participants must use effective contraception during treatment and 6 months after last dose; female participants non-lactating, negative serum HCG within 14 days pre-first dose.
- Voluntarily sign written informed consent, good compliance for follow-up.
Exclusion Criteria:
- Mixed small cell/large cell neuroendocrine/sarcomatoid NSCLC histology.
- Concurrent other actionable driver gene alterations (EGFR, ALK, MET, BRAF, RET etc.) besides HER2.
- Past or concurrent other malignant tumor (except fully resected cancer ≥5 years without active treatment).
- Prior thoracic radiotherapy.
- Major surgery within 28 days or minor invasive surgery within 7 days before first dose.
- HIV infection, active hepatitis B/C, organ transplant history, congenital/acquired immunodeficiency.
- Systemic immune modulators (thymosin, interferon, IL-2) within 4 weeks pre-enrollment.
- Uncontrolled severe cardiovascular disease, unstable angina or intervention-required ventricular arrhythmia within 1 month.
- Confirmed or suspected interstitial lung disease, severe baseline pulmonary dysfunction interfering with lung toxicity monitoring.
- Active uncontrolled ≥2 grade infection within 2 weeks before enrollment.
- Active tuberculosis under treatment.
- Known hypersensitivity to any component of study drugs or other monoclonal antibodies/fusion proteins.
- Any condition judged by investigator to compromise participant safety or trial compliance.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Experimental: Adebrelimab + Trastuzumab rezetecan Induction Therapy
|
1200mg intravenous infusion on Day 1 of every 21-day cycle for 3-4 induction cycles; consolidation therapy after local treatment as physician discretion.
Infusion duration 30-60 minutes.
3.2mg/kg intravenous infusion on Day 1 of every 21-day cycle for 3-4 induction cycles; fixed dose 408mg if body weight ≥85kg.
First infusion over 90 mins, subsequent cycles 60 mins if well tolerated.
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective Response Rate (ORR)
Délai: End of Cycle 3/Cycle 4 induction (each cycle 21 days). Surgery-eligible patients assess tumor 6-8 weeks after Cycle3 last dose; others evaluate at Cycle4 end, ±7-day imaging window.
|
Proportion of participants achieving Complete Response (CR) or Partial Response (PR) after 3-4 cycles induction therapy, assessed per RECIST v1.1 by investigators
|
End of Cycle 3/Cycle 4 induction (each cycle 21 days). Surgery-eligible patients assess tumor 6-8 weeks after Cycle3 last dose; others evaluate at Cycle4 end, ±7-day imaging window.
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Surgical Conversion Rate
Délai: Within 6 to 8 weeks after the last induction study drug infusion (42-56 days post final induction dose)
|
Percentage of subjects receiving R0 radical pulmonary resection after MDT re-evaluation post induction
|
Within 6 to 8 weeks after the last induction study drug infusion (42-56 days post final induction dose)
|
|
Major Pathological Response (MPR) Rate
Délai: Within 4 weeks after curative lung resection (pathology report completion window)
|
Proportion of surgical patients with ≤10% viable tumor cells in resected primary tumor specimen (central blinded pathology review)
|
Within 4 weeks after curative lung resection (pathology report completion window)
|
|
Event-Free Survival (EFS)
Délai: Up to 36 months after the first dose of study treatment (3-year full survival follow-up)
|
Time from first study drug dose to disease progression, local recurrence, distant metastasis, or death from any cause
|
Up to 36 months after the first dose of study treatment (3-year full survival follow-up)
|
|
Overall Survival (OS)
Délai: 12 months, 18 months, 24 months, and 36 months after the first dose of study treatment
|
OS defined as time from first dose to all-cause death; survival rate calculated at fixed time points
|
12 months, 18 months, 24 months, and 36 months after the first dose of study treatment
|
|
Safety Profile (Treatment-Related Adverse Events)
Délai: From the date of signed informed consent through 30 days after the last study treatment infusion; long-term safety follow-up continues up to 36 months post first dose for delayed irAEs.
|
Incidence and grade of all adverse events, ≥3 grade AEs, serious adverse events (SAE), immune-related AEs, interstitial lung disease graded per NCI CTCAE v6.0
|
From the date of signed informed consent through 30 days after the last study treatment infusion; long-term safety follow-up continues up to 36 months post first dose for delayed irAEs.
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- NSCLC-HER2-II-001
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .